Mediators of Inflammation

Mediators of Inflammation / 2014 / Article

Research Article | Open Access

Volume 2014 |Article ID 898630 |

Roland Meisel, Kathrin Heseler, Julia Nau, Silvia Kathrin Schmidt, Margret Leineweber, Sabine Pudelko, Johannes Wenning, Albert Zimmermann, Hartmut Hengel, Christian Sinzger, Özer Degistirici, Rüdiger Volker Sorg, Walter Däubener, "Cytomegalovirus Infection Impairs Immunosuppressive and Antimicrobial Effector Functions of Human Multipotent Mesenchymal Stromal Cells", Mediators of Inflammation, vol. 2014, Article ID 898630, 7 pages, 2014.

Cytomegalovirus Infection Impairs Immunosuppressive and Antimicrobial Effector Functions of Human Multipotent Mesenchymal Stromal Cells

Academic Editor: Eduardo López-Collazo
Received12 Dec 2013
Accepted10 Feb 2014
Published23 Mar 2014


Human mesenchymal stromal cells (MSC) possess immunosuppressive and antimicrobial effects that are partly mediated by the tryptophan-catabolizing enzyme indoleamine-2,3-dioxygenase (IDO). Therefore MSC represent a promising novel cellular immunosuppressant which has the potential to control steroid-refractory acute graft versus host disease (GvHD). In addition, MSC are capable of reducing the risk of infection in patients after haematopoietic stem cell transplantation (HST). Recent data indicate that signals from the microenvironment including those from microbes may modulate MSC effector functions. As Cytomegalovirus (CMV) represents a prominent pathogen in immunocompromised hosts, especially in patients following HST, we investigated the impact of CMV infection on MSC-mediated effects on the immune system. We demonstrate that CMV-infected MSC lose their cytokine-induced immunosuppressive capacity and are no longer able to restrict microbial growth. IDO expression is substantially impaired following CMV infection of MSC and this interaction critically depends on intact virus and the number of MSC as well as the viral load. Since overt CMV infection may undermine the clinical efficacy of MSC in the treatment of GvHD in transplant patients, we recommend that patients scheduled for MSC therapy should undergo thorough evaluation for an active CMV infection and receive CMV-directed antiviral therapy prior to the administration of MSC.

1. Introduction

Human multipotent mesenchymal stromal cells (MSC), known for their multilineage differentiation potential, possess pleiotropic immunosuppressive functions that are partly mediated by expression of the tryptophan-catabolizing enzyme indoleamine-2,3-dioxygenase (IDO) [14]. Upon stimulation with inflammatory cytokines, MSC exhibit broad-spectrum antimicrobial effector functions directed against various clinically relevant pathogens, and these effects are dependent on IDO and/or the antimicrobial peptide LL-37 [5, 6]. These dual immunosuppressive and antimicrobial properties render MSC a promising novel cellular immunosuppressant which is currently under intensive clinical investigation for various auto- and alloimmune diseases such as steroid-refractory graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT), Crohn’s disease, and multiple sclerosis [710]. Emerging data indicate that signals from the microenvironment including those induced by hypoxia [11, 12] or derived from microbes may critically affect IDO and consequently MSC effector functions [1315]. As the Cytomegalovirus (CMV) represents a prominent pathogen in immunocompromised hosts in particular in patients suffering from GvHD after HSCT, we initiated studies investigating the impact of CMV infection on MSC-mediated effects. During coevolution with its specific host, human CMV has developed several immune evasion strategies [1618]. For example, CMV has been reported to inhibit the upregulation of MHC class II antigens. Furthermore, it was found that CMV generally inhibits signalling via the IFN-γ receptor and that this is mediated via a reduced phosphorylation of STAT1 and an enhanced degradation of Jak1 [1921].

Mesenchymal stromal cells and embryonic stem cells are able to inhibit T-cell responses and several mechanisms including the production of prostaglandins, of immunosuppressive cytokines [3], of arginase I [22], or of adenosine [23, 24] appear to be involved in this effect. In addition, we and others reported that the immunoregulatory effects of mesenchymal stromal cells are, at least in part, brought about by the induction of the tryptophan degrading enzyme indoleamine 2,3-dioxygenase [4].

We report here that CMV is a major negative regulator of IDO activity in human MSC, dramatically reducing their immunosuppressive and antimicrobial properties, thereby implicating that active CMV infections may undermine the clinical efficacy of MSC treatment.

2. Materials and Methods

2.1. Primary Cells

Human bone marrow-derived MSC were prepared, propagated, and characterized as previously described [5]. Bone marrow aspirates for the generation of MSC were obtained from healthy volunteer donors who had provided written informed consent; the study was conducted according to the Declaration of Helsinki principles and approved by the ethics committee of the Medical Faculty of the Heinrich-Heine-University, Düsseldorf, Germany.

2.2. Cell Lines and Reagents

OKT3 producing hybridoma cells were obtained from the American Type Culture Collection (Rockville, USA). Recombinant human IFN-γ was purchased from R&D Systems (Wiesbaden, Germany). L-Tryptophan, L-kynurenine, 1-L-methyl-tryptophan (1-MT), and Ehrlich’s reagent were ordered from Sigma-Aldrich (Deisenhofen, Germany).

2.3. Human Cytomegalovirus

CMV strains AD169 and TB40E were kindly provided by C. Sinzger (Institute for Medical Virology, Ulm, Germany) and A. Zimmermann (Institute for Virology, Düsseldorf, Germany). Before infection of MSC, the virus-containing solution was thawed and diluted in tryptophan-free RPMI 1640 medium to reach a multiplicity of infection (MOI) of 0.1–10. In some experiments UV-inactivated CMV preparations were used. Viral replication was analysed using real-time PCR as described [5].

2.4. Kynurenine Assay

The enzymatic activity of IDO directly correlates with the concentration of kynurenine in supernatants of tissue culture cells and therefore, the measurement of kynurenine can be used to determine IDO activity [25]. MSC (2 × 104 per well) were plated in 96-well flat-bottomed microtiter plates in IMDM containing 5% FCS and 0.6 mM L-tryptophan. The cultures were stimulated with IFN-γ at concentrations indicated in the respective experiments. The plates were incubated at 37°C and after 72 h 160 μL were removed from each well and transferred to a 96-well V-bottomed plate. After the addition of 10 μL 30% trichloroacetic acid to each well, the plates were incubated at 50°C for 30 minutes to hydrolyze N-formyl-kynurenine to kynurenine. After centrifugation for 10 min at 600 g, 100 μL supernatant was transferred to 96-well flat-bottomed plates and 100 μL 1.2% (w/v) 4-(dimethylamino) benzaldehyde (Ehrlich’s reagent) in glacial acetic acid was added. After 10 minutes at room temperature, the extinction was determined at 492 nm with a microplate reader (Tecan, Crailsheim, Germany). Data are given as mean kynurenine content of triplicate cultures. In some experiments IDO was induced by coculturing MSC with OKT3-stimulated peripheral blood lymphocytes for three days. As a control 1-L-MT (1.5 mM) or a neutralizing anti-IFN-γ antibody (10 ng/mL) was added at the time point of MSC stimulation. In addition, IDO protein was detected in stimulated MSC using Western blot analysis as described [5].

2.5. T-Cell Proliferation Assay

1 × 105 peripheral blood lymphocytes (PBL), obtained from heparinised blood of healthy donors after Ficoll purification, were stimulated with a monoclonal anti-CD3 antibody (OKT3, American Type Culture Collection, Rockville, USA) in the presence of different amounts of MSC as described [26]. In some experiments MSC (0.5–2 × 104 per well) were infected with CMV and/or stimulated with IFN-γ at the start of the culture. After three days the cultures were pulsed with 0.2 μCi [3H] thymidine for 24 hours. T-cell proliferation was measured by [3H] thymidine incorporation using liquid scintillation spectrometry (1205 Betaplate, PerkinElmer, Jugesheim, Germany).

2.6. Staphylococcus aureus

MSC were infected with 10–100 cfu/well. Bacterial growth was monitored after further incubation of 16 h by measuring optical density at 620 nm [27].

2.7. Statistical Analysis

All data are given as mean ± SEM of at least 3 independent experiments and each experiment was performed in triplicate. Data of representative experiments, also performed in triplicate, were given as mean ± SD. For the comparison of different data Student’s -test for unpaired groups was used and the value was calculated using GraphPad Prism software.

3. Results and Discussion

The profound T-cell inhibitory capacity of human multipotent mesenchymal stromal cells has raised much interest promting studies investigating MSC as a novel cellular immunosuppressant, in particular in steroid-refractory GvHD after HSCT. To explore the potential impact of CMV infections on the therapeutic efficacy of MSC in this setting, we set up a three-party cell culture system, in which OKT3-induced T-cell proliferation was assessed in the presence or absence of human MSC that were infected with CMV at a multiplicity of infection 5 (MOI 5) or left untreated. As shown in Figure 1 we found a profound T-cell inhibitory effect of MSC, which was partially but significantly reversed in the presence of CMV. This effect, however, did not rely on CMV-directed T-cell responses as CMV-infected MSC did not induce any T-cell proliferation in the absence of OKT3 stimulation (Figure 1). In addition, T cells from our donors did not proliferate in the presence of CMV and CMV did not significantly alter the T-cell response after stimulation with anti-CD3 antibodies as shown in Figure 2(a). We have previously shown that the induction of IDO is, at least in part, responsible for the reduced T-cell proliferation induced by MSC [4]. To prove this finding we used the IDO inhibitor 1-L-methyl-tryptophan (1MT). As shown in Figure 2(b) human MSCs inhibited T-cell responses and this inhibitory effect could be abrogated by the addition of CMV or of 1-MT.

To substantiate these experimental findings, we performed a series of 15 subsequent experiments employing various numbers of CMV-infected MSC. We found that 2 × 104 MSC provided substantial suppression of T-cell proliferation and the addition of CMV consistently antagonizes this T-cell inhibitory effect. In all 15 experiments performed an inhibitory effect of CMV on MSC-mediated T-cell suppression was observed; however, the magnitude of this effect varied (Figure 3(a)). In contrast, 5 × 103 MSC were unable to restrict T-cell proliferation and, under these conditions, the same amount of CMV that was employed in the experiments shown in Figure 3(b) did not have any impact on T cells, thus ruling out an unspecific effect of CMV. Taken together, this data demonstrates that CMV infection of human MSC substantially impedes their T-cell inhibitory effector function.

In previous studies we and others have identified a significant role of the IFN-γ-inducible tryptophan-catabolizing enzyme indoleamine-2,3-dioxygenase (IDO) in MSC-mediated T-cell inhibition [4, 28]. In additional studies, the role of IDO in tolerance induction was demonstrated in in vivo studies using IDO deficient animals [29]. Based on these findings we went on to assess the impact of CMV infection on cytokine-induced IDO activity of human MCS. As shown in Figure 4(a), we observed a substantial IDO-mediated kynurenine production when MSC were cultured in the presence of OKT3-activated T cells. As expected, IDO activity induced in MSC by activated T cells could be blocked by neutralising antibodies directed against IFN-γ as well as by the IDO-specific inhibitor 1-L-methyl-tryptophan. However, it is of particular interest that CMV-infected MSC were unable to express IDO activity in the presence of activated T cells, while UV-inactivated CMV preparations had no impact on IDO activity. Thus, an infection with replication-competent CMV substantially impairs IFN-γ-induced IDO expression in human MSC.

In addition to their immunosuppressive capacity, MSC have recently been shown to possess cell-autonomous antimicrobial effects directed against various clinically relevant pathogens [5, 6, 15]. We therefore proceeded to analyse the potential impact of CMV on MSC-mediated antibacterial effects induced by cytokines released from OKT3-stimulated T cells. As shown in Figure 4(b), MSC cocultured with activated T cells are able to restrict bacterial growth and CMV infection of MSC abrogated their antimicrobial effect against Staphylococcus aureus. The functional relevance of IDO-mediated antibacterial effects was confirmed by demonstrating that addition of excess amounts of tryptophan completely abolished the antimicrobial effector function of MSC (Figure 4(b)).

In additional experiments we analysed CMV-mediated inhibition of IFN-γ induced IDO activity in human MSC in more detail. We found that CMV infection impairs cytokine-induced IDO activity of human MSC in a dose-dependent manner with significant inhibition observed at CMV doses as low as a MOI of 0.6 and with a maximum effect at a MOI of 5 (Figure 5(a)). Furthermore, Western blot analysis, depicted in Figure 5(b), showed that CMV infection of MSC results in a reduced expression of IDO protein.

In our present work we describe for the first time that a CMV infection critically impairs the immunosuppressive and antimicrobial effector functions of human MSC possibly via an interaction with the IFN-γ-induced IDO pathway. We demonstrate that this interaction between CMV and IDO-mediated effector functions of stromal cells critically depends on intact virus as well as the number of host cells and virus employed.

We have recently reported that human fibroblasts lose their immunosuppressive capacity after a CMV infection and that this finding might be relevant for host-versus-graft reaction disease triggered by CMV infection/reactivation after solid organ transplantation [26]. Here we show that a similar CMV-mediated effect on MSC might influence the clinical effectivity of these cells as immunosuppressant.

We are aware of the fact that our observations are derived from in vitro cell culture experiments. In the in vivo situation an immunosuppressive therapy, necessary in transplant patients, might result in an inhibition of IFN-γ production and therefore inhibit IDO induction [30]. Immunosuppressive substances such as glucocorticoides at high concentrations are able to enhance IDO activity [31, 32]. Furthermore the broad organ tropism, different cell types, and differences in cell tropism might have an impact on CMV-mediated inhibition of IDO activation [33]. However, based on the species specificity of CMV infection as well as IDO expression [5, 34], murine in vivo experiments including humanized xenograft models will unfortunately not be informative with regard to the in vivo impact of a CMV infection on MSC-mediated immunosuppressive and antimicrobial effects.

We put a particular focus on MSC in our study as these cells represent a promising novel therapeutic approach for a variety of clinical applications ranging from tissue engineering and regenerative medicine to the treatment of auto- and alloimmune diseases refractory to conventional pharmacologic immunosuppression [35, 36]. One might speculate that the inhibitory interaction of CMV with IDO-mediated immunosuppressive effects may explain the consistent clinical observation that CMV infection frequently triggers GvHD following hematopoietic stem cell transplantation [37].

The findings presented here may have implications for transplantation medicine and the future clinical use of MSC. We found that MSC and fibroblasts are permissive for CMV infection and are able to inhibit viral growth due to IDO-dependent mechanisms [5]. Both cell types are also sensitive to CMV-mediated immune escape mechanisms [26]. We suggest that the balance between IFN-γ dose-dependent IDO induction and CMV dose-dependent IDO inhibition might influence the clinical outcome of organ or stem cell transplantation in CMV-infected patients. We are aware that the magnitude of virus load and of IFN-γ concentrations in virus plaques within infected human tissues is unknown. However we recommend that patients scheduled for MSC therapy should undergo thorough evaluation for an active CMV infection and receive CMV-directed antiviral therapy prior to administration of MSC, if appropriate, since overt CMV infection of MSC recipients may undermine the clinical efficacy of the MSC treatment.

Thus, strategies that aim at restoring IDO expression in CMV-infected MSC may prove beneficial in certain clinical scenarios. Further studies characterizing the distinct signalling pathways that are targeted by CMV and result in modulation of IDO expression in MSC are necessary to identify molecular targets for therapeutic intervention.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Roland Meisel and Kathrin Heseler share first authorship.


The authors thank Silke Stuhlsatz, Institute for Medical Microbiology and Hospital Hygiene, Heinrich-Heine-University Düsseldorf, for expert technical assistance. This study was supported by German Federal Ministry of Education and Research (BMBF) Grants no. 01GN0951 (Walter Däubener, Rüdiger Volker Sorg), no. 01KI1002E (Walter Däubener), no. 01GN0990 (Roland Meisel), and no. 01GM0873 (Roland Meisel), German Research Council (DFG) Grant no. RU 729 (Walter Däubener), and “Forschungskommission Universitätsklinik Düsseldorf” (Walter Däubener).


  1. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at: Publisher Site | Google Scholar
  2. A. I. Caplan, “Adult mesenchymal stem cells for tissue engineering versus regenerative medicine,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 341–347, 2007. View at: Publisher Site | Google Scholar
  3. A. J. Nauta and W. E. Fibbe, “Immunomodulatory properties of mesenchymal stromal cells,” Blood, vol. 110, no. 10, pp. 3499–3506, 2007. View at: Publisher Site | Google Scholar
  4. R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, “Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation,” Blood, vol. 103, no. 12, pp. 4619–4621, 2004. View at: Publisher Site | Google Scholar
  5. R. Meisel, S. Brockers, K. Heseler et al., “Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase,” Leukemia, vol. 25, no. 4, pp. 648–654, 2011. View at: Google Scholar
  6. A. Krasnodembskaya, Y. Song, X. Fang et al., “Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37,” Stem Cells, vol. 28, no. 12, pp. 2229–2238, 2010. View at: Publisher Site | Google Scholar
  7. K. Le Blanc, F. Frassoni, L. Ball et al., “Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study,” The Lancet, vol. 371, no. 9624, pp. 1579–1586, 2008. View at: Publisher Site | Google Scholar
  8. M. Duijvestein, A. C. W. Vos, H. Roelofs et al., “Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study,” Gut, vol. 59, no. 12, pp. 1662–1669, 2010. View at: Publisher Site | Google Scholar
  9. A. Uccelli, S. Morando, S. Bonanno, I. Bonanni, A. Leonardi, and G. Mancardi, “Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter?” Current Stem Cell Research and Therapy, vol. 6, no. 1, pp. 69–72, 2011. View at: Publisher Site | Google Scholar
  10. L. M. Ball, M. E. Bernardo, H. Roelofs et al., “Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease,” British Journal of Haematology, vol. 163, no. 4, pp. 501–509, 2013. View at: Google Scholar
  11. A. Roth., P. König, V. G. Zandbergen et al., “Hypoxia abrogates antichlamydial properties of IFN-γ in human fallopian tube cells in vitro and ex vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 45, pp. 19502–19507, 2010. View at: Publisher Site | Google Scholar
  12. S. K. Schmidt, S. Ebel, E. Keil et al., “Regulation of IDO activity by oxygen supply: inhibitory effects on antimicrobial and immunoregulatory functions,” PLoS ONE, vol. 8, no. 5, Article ID e63301, 2013. View at: Google Scholar
  13. F. Liotta, R. Angeli, L. Cosmi et al., “Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing notch signaling,” Stem Cells, vol. 26, no. 1, pp. 279–289, 2008. View at: Publisher Site | Google Scholar
  14. C. A. Opitz, U. M. Litzenburger, C. Lutz et al., “Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via Interferon-b and protein kinase R,” Stem Cells, vol. 27, no. 4, pp. 909–919, 2009. View at: Publisher Site | Google Scholar
  15. J. J. Auletta, R. J. Deans, and A. M. Bartholomew, “Emerging roles for multipotent, bone marrow-derived stromal cells in host defense,” Blood, vol. 119, no. 8, pp. 1801–1809, 2012. View at: Publisher Site | Google Scholar
  16. M. K. Gandhi and R. Khanna, “Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments,” Lancet Infectious Diseases, vol. 4, no. 12, pp. 725–738, 2004. View at: Publisher Site | Google Scholar
  17. V. Noriega, V. Redmann, T. Gardner, and D. Tortorella, “Diverse immune evasion strategies by human cytomegalovirus,” Immunologic Research, vol. 54, no. 1–3, pp. 140–151, 2012. View at: Publisher Site | Google Scholar
  18. G. Rossini, C. Cerboni, A. Santoni et al., “Interplay between human cytomegalovirus and intrinsic/innate host responses: a complex bidirectional relationship,” Mediators of Inflammation, vol. 2012, Article ID 607276, 16 pages, 2012. View at: Publisher Site | Google Scholar
  19. V. T. K. Le, M. Trilling, M. Wilborn, H. Hengel, and A. Zimmermann, “Human cytomegalovirus interferes with Signal Transducer and Activator of Transcription (STAT) 2 protein stability and tyrosine phosphorylation,” Journal of General Virology, vol. 89, no. 10, pp. 2416–2426, 2008. View at: Publisher Site | Google Scholar
  20. D. M. Miller, B. M. Rahill, J. M. Boss et al., “Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway,” Journal of Experimental Medicine, vol. 187, no. 5, pp. 675–683, 1998. View at: Publisher Site | Google Scholar
  21. M. Baron and J.-L. Davignon, “Inhibition of IFN-γ-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2,” Journal of Immunology, vol. 181, no. 8, pp. 5530–5536, 2008. View at: Google Scholar
  22. N. Yachimovich-Cohen, S. Even-Ram, Y. Shufaro, J. Rachmilewitz, and B. Reubinoff, “Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism,” Journal of Immunology, vol. 184, no. 3, pp. 1300–1308, 2010. View at: Publisher Site | Google Scholar
  23. F. Saldanha-Araujo, F. I. S. Ferreira, P. V. Palma et al., “Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes,” Stem Cell Research, vol. 7, no. 1, pp. 66–74, 2011. View at: Publisher Site | Google Scholar
  24. C. Sattler, M. Steinsdoerfer, M. Offers et al., “Inhibition of T-cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation,” Cell Transplantation, vol. 20, no. 8, pp. 1221–1230, 2011. View at: Publisher Site | Google Scholar
  25. W. Däubener, N. Wanagat, K. Pilz, S. Seghrouchni, H. G. Fischer, and U. Hadding, “A new, simple, bioassay for human IFN-γ,” Journal of Immunological Methods, vol. 168, no. 1, pp. 39–47, 1994. View at: Publisher Site | Google Scholar
  26. K. Heseler, S. K. Schmidt, K. Spekker et al., “Cytomegalovirus impairs the induction of indoleamine 2, 3-dioxygenase mediated antimicrobial and immunoregulatory effects in human fibroblasts,” PLoS ONE, vol. 8, no. 5, Article ID e64442, 2013. View at: Google Scholar
  27. A. Müller, K. Heseler, S. K. Schmidt, K. Spekker, C. R. MacKenzie, and W. Däubener, “The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects,” Journal of Cellular and Molecular Medicine, vol. 13, no. 6, pp. 1125–1135, 2009. View at: Publisher Site | Google Scholar
  28. M. Di Trapani, G. Bassi, M. Ricciardi et al., “Comparative study of immune regulatory properties of stem cells derived from different tissues,” Stem Cells and Development, vol. 22, no. 22, pp. 2990–3002, 2013. View at: Google Scholar
  29. W. Ge, J. Jiang, J. Arp, W. Liu, B. Garcia, and H. Wang, “Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression,” Transplantation, vol. 90, no. 12, pp. 1312–1320, 2010. View at: Publisher Site | Google Scholar
  30. S. Schroecksnadel, R. Sucher, K. Kurz, D. Fuchs, and G. Brandacher, “Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells,” Transplant Immunology, vol. 25, no. 2-3, pp. 119–123, 2011. View at: Publisher Site | Google Scholar
  31. J. Turck, C. Oberdorfer, T. Vogel et al., “Enahncement of antimicrobial effects by glucocorticoids,” Medical Microbiology and Immunology, vol. 194, no. 1-2, pp. 47–53, 2005. View at: Google Scholar
  32. U. Grohmann, C. Volpi, F. Fallarino et al., “Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy,” Nature Medicine, vol. 13, no. 5, pp. 579–586, 2007. View at: Publisher Site | Google Scholar
  33. L. Scrivano, C. Sinzger, H. Nitschko, U. H. Koszinowski, and B. Adler, “HCMV spread and cell tropism are determined by distinct virus populations,” PLoS Pathogens, vol. 7, no. 1, Article ID e1001256, 2011. View at: Publisher Site | Google Scholar
  34. G. Ren, J. Su, L. Zhang et al., “Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression,” Stem Cells, vol. 27, no. 8, pp. 1954–1962, 2009. View at: Publisher Site | Google Scholar
  35. A. I. Caplan and D. Correa, “The MSC: an injury drugstore,” Cell Stem Cell, vol. 9, no. 1, pp. 11–15, 2011. View at: Publisher Site | Google Scholar
  36. K. English, A. French, and K. J. Wood, “Mesenchymal stromal cells: facilitators of successful transplantation?” Cell Stem Cell, vol. 7, no. 4, pp. 431–442, 2010. View at: Publisher Site | Google Scholar
  37. N. Cantoni, H. H. Hirsch, N. Khanna et al., “Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease,” Biology of Blood and Marrow Transplantation, vol. 16, no. 9, pp. 1309–1314, 2010. View at: Publisher Site | Google Scholar

Copyright © 2014 Roland Meisel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles